Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
REGNthis companyRegeneron Pharmaceuticals, Inc.	$923.95	17.92×	2.58×	5.63×	13.81×	118.6%	85.4%	24.9%	31.4%	14.4%	8.5%	5.1%	0.09×	-0.07×	81.69×	4.13×	0.5%	6	7.59	4	A
AMGNAmgen Inc.	$464.69	22.84×	20.34×	4.79×	13.11×	93.9%	70.8%	29.1%	21.0%	89.1%	13.2%	4.6%	6.31×	2.69×	3.88×	1.14×	2.9%	8	2.55	3	B+
BIIBBiogen Inc.	$257.70	19.89×	1.41×	2.63×	10.1×	99.0%	70.5%	19.1%	13.2%	7.1%	6.6%	7.9%	0.38×	1.34×	7.63×	2.68×	0.0%	5	3.11	3	B
EYPTEyePoint Pharmaceuticals, Inc.	$0.37	-5.76×	4.37×	42.66×	-5.49×	-1272.4%	93.4%	-776.0%	-739.4%	-75.8%	-74.0%	-18.2%	0.07×	0.34×	0×	8.88×	0.0%	2	-11.11	1	C-
GILDGilead Sciences, Inc.	$169.76	17.94×	6.73×	5.19×	12.52×	-19.1%	78.8%	39.7%	28.9%	37.5%	20.3%	6.2%	1.1×	1.28×	11.43×	1.55×	2.6%	5	3.9	1	C-
OCULOcular Therapeutix, Inc.	$6.76	-8.55×	3.47×	43.86×	-6.47×	-101.8%	87.3%	-521.0%	-513.2%	-40.6%	-35.5%	-9.5%	0.12×	2.63×	-22.82×	15.39×	0.0%	3	1.33	1	C-
Peer median	—	17.94×	4.37×	5.19×	10.1×	-19.1%	78.8%	19.1%	13.2%	7.1%	6.6%	4.6%	0.38×	1.34×	3.88×	2.68×	0.0%	5	2.55	1	—